AVXLAnavex Life Sciences Corp.

AVXL Stock Price, Valuation & Chart | Anavex Life Sciences Corp.

Compare

$2.870+0.07 (+2.50%)

At close · 01 Sept 2026, 08:00 pm

Sector: Healthcare Industry: Biotechnology AVXL intrinsic value AVXL calculated fair value vs price

Overview Financials Dividends Ratios

AVXL Historical price chart

AVXL Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization265.97M

PE Ratio-18.1

EPS-0.16

Trading Volume826.63K

Today's High/Low2.9/2.75

Dividend Yield0.00

52 Week High/Low10.4/2.25

Shares Outstanding92.67M

AVXL Financial Statement

AVXL Analyst ratings

AVXL Analysis & performance metrics

AVXL Company profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS)…

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical…

AVXL Management team

Name

Position

Adebayo Laniyonu Ph.D.

Senior Vice President of Nonclinical Development

Christopher U. Missling M.B.A., M.S., Ph.D.CEO

President, Chief Executive Officer, Secretary & Director

Clint Tomlinson

Vice President of Corporate

Edward R Hammond M.D., M.P.H., Ph.D.

Chief Medical Officer

Terrie Kellmeyer Ph.D.

Senior Vice President of Clinical Development

Juan Carlos Lopez-Talavera M.D., Ph.D.

Senior Vice President & Head of Research and Development

Kun Jin Ph.D.

Head of Biostatistics

Sandra Boenisch CPA, CGA

Principal Financial Officer & Treasurer

Name

Position

Adebayo Laniyonu Ph.D.

Senior Vice President of Nonclinical Development

Christopher U. Missling M.B.A., M.S., Ph.D.CEO

President, Chief Executive Officer, Secretary & Director

Clint Tomlinson

Vice President of Corporate

Edward R Hammond M.D., M.P.H., Ph.D.

Chief Medical Officer

Terrie Kellmeyer Ph.D.

Senior Vice President of Clinical Development

Juan Carlos Lopez-Talavera M.D., Ph.D.

Senior Vice President & Head of Research and Development

Kun Jin Ph.D.

Head of Biostatistics

Sandra Boenisch CPA, CGA

Principal Financial Officer & Treasurer

Management Team

Adebayo Laniyonu Ph.D.

Senior Vice President of Nonclinical Development

Christopher U. Missling M.B.A., M.S., Ph.D.CEO

President, Chief Executive Officer, Secretary & Director

Clint Tomlinson

Vice President of Corporate

Edward R Hammond M.D., M.P.H., Ph.D.

Chief Medical Officer

Terrie Kellmeyer Ph.D.

Senior Vice President of Clinical Development

Juan Carlos Lopez-Talavera M.D., Ph.D.

Senior Vice President & Head of Research and Development

Kun Jin Ph.D.

Head of Biostatistics

Sandra Boenisch CPA, CGA

Principal Financial Officer & Treasurer

Management

Adebayo Laniyonu Ph.D.

Senior Vice President of Nonclinical Development

Christopher U. Missling M.B.A., M.S., Ph.D.CEO

President, Chief Executive Officer, Secretary & Director

Clint Tomlinson

Vice President of Corporate

Edward R Hammond M.D., M.P.H., Ph.D.

Chief Medical Officer

Terrie Kellmeyer Ph.D.

Senior Vice President of Clinical Development

Juan Carlos Lopez-Talavera M.D., Ph.D.

Senior Vice President & Head of Research and Development

Kun Jin Ph.D.

Head of Biostatistics

Sandra Boenisch CPA, CGA

Principal Financial Officer & Treasurer

Total 8 executives

AVXL Frequently asked questions

What is Anavex Life Sciences Corp. (AVXL) Stock Price?

Current stock price of Anavex Life Sciences Corp. (AVXL) stock is $2.870. The stock price is +2.50% higher in the session. The intraday range can be seen from this page. Volume of Anavex Life Sciences Corp. (AVXL) stock is 826.63K.

Last updated at 01 Sept 2026, 08:00 pm.

Why is the Anavex Life Sciences Corp. (AVXL) stock price going up or down today?

The stock price of Anavex Life Sciences Corp. (AVXL) can change with earnings, company news, and overall market sentiment. Anavex Life Sciences Corp. operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Anavex Life Sciences Corp. stock expensive at its current price?

Whether Anavex Life Sciences Corp. looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for AVXL on this page is -18.10. EPS on this page is -0.16. Compare those figures with peers and growth expectations before deciding if the current Anavex Life Sciences Corp. price is justified.

How has the stock price of Anavex Life Sciences Corp. (AVXL) performed historically?

Historical performance for Anavex Life Sciences Corp. (AVXL) is shown on the price chart on this page. Review multi-period moves alongside volume to see how AVXL reacted to past earnings and market events.

Should I buy Anavex Life Sciences Corp. (AVXL) stock, at this price?

Buying Anavex Life Sciences Corp. (AVXL) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.